EC 231-116-1
Also known as Pt.
chemXplore tracks 2 projects producing platinum, of which 2 are active.
Of the active ones, 1 new construction and 1 expansion.
Operating profit rose 45% to £170 million, while Clean Air margins improved and the group advanced its portfolio reshaping.
The accelerated approval covers adults with advanced disease after alectinib alone, or after at least two ALK inhibitors and platinum chemotherapy.
The project adds cobalt recycling and targets €60m in annual savings by Q4 2028; FY 2026 adjusted EBITDA guidance remains slightly above €1bn.
The project will track iridium and ruthenium from spent electrodes through refining and reuse in new electrodes.
Phase 3 TroFuse‑005 showed a 32% lower risk of death and 41% lower risk of progression or death, with a PDUFA target date of June 15, 2027.
Durable PFS and DOR not reached with immunotherapy combo; chemoimmunotherapy combo showed 62% ORR and 14.5‑month median DOR in first-line KRAS G12C NSCLC.
Sofe‑M plus bevacizumab produced a 79% confirmed objective response rate and 100% disease control in platinum‑sensitive ovarian cancer, with activity across FRα levels and prior PARPi exposure.
Phase 3 DeLLphi‑305: IMDELLTRA with durvalumab raised median OS to 21.1 vs 12.7 months, tripled PFS, and produced ~80% one‑year survival versus 53%.
Phase Ib BEHOLD‑1 reports durable responses and 11.1‑month median PFS at the selected phase III dose; safety predominantly haematologic with most grade ≥3 events.
Phase 3 intismeran combo improved recurrence‑free and distant metastasis‑free survival in resected stage IIB–IV melanoma; sac‑TMT and KEYNOTE‑C93 report pivotal endometrial cancer findings; >90 additional abstracts.
A subscription lists every plant we track for platinum, with its owners and capacity. What a subscription does